PACIFIC BIOSCIENCES OF CALIF (PACB)
US69404D1081 - Common Stock
Taking everything into account, PACB scores 2 out of 10 in our fundamental rating. PACB was compared to 55 industry peers in the Life Sciences Tools & Services industry. PACB has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, PACB is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year PACB has reported negative net income.
In the past year PACB has reported a negative cash flow from operations.
In the past 5 years PACB reported 4 times negative net income.
PACB had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
The Return On Assets of PACB (-27.19%) is worse than 70.91% of its industry peers.
With a Return On Equity value of -87.01%, PACB is not doing good in the industry: 81.82% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -27.19% | ||
| ROE | -87.01% | ||
| ROIC | N/A |
ROA(3y)-14.79%
ROA(5y)-18.82%
ROE(3y)-40.82%
ROE(5y)-53.38%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
PACB's Gross Margin of 23.81% is on the low side compared to the rest of the industry. PACB is outperformed by 81.82% of its industry peers.
In the last couple of years the Gross Margin of PACB has declined.
PACB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 23.81% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.13%
GM growth 5Y-2.57%
2. Health
2.1 Basic Checks
PACB does not have a ROIC to compare to the WACC, probably because it is not profitable.
PACB has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, PACB has more shares outstanding
Compared to 1 year ago, PACB has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -1.94, we must say that PACB is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of PACB (-1.94) is worse than 78.18% of its industry peers.
A Debt/Equity ratio of 1.97 is on the high side and indicates that PACB has dependencies on debt financing.
The Debt to Equity ratio of PACB (1.97) is worse than 85.45% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.97 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.94 |
ROIC/WACCN/A
WACC6.56%
2.3 Liquidity
A Current Ratio of 9.74 indicates that PACB has no problem at all paying its short term obligations.
The Current ratio of PACB (9.74) is better than 89.09% of its industry peers.
A Quick Ratio of 8.64 indicates that PACB has no problem at all paying its short term obligations.
PACB has a better Quick ratio (8.64) than 87.27% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 9.74 | ||
| Quick Ratio | 8.64 |
3. Growth
3.1 Past
PACB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -11.02%.
PACB shows a small growth in Revenue. In the last year, the Revenue has grown by 2.15%.
PACB shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 20.60% yearly.
EPS 1Y (TTM)-11.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.62%
Revenue 1Y (TTM)2.15%
Revenue growth 3Y36.47%
Revenue growth 5Y20.6%
Sales Q2Q%-28.23%
3.2 Future
Based on estimates for the next years, PACB will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.81% on average per year.
PACB is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 16.75% yearly.
EPS Next Y-7.52%
EPS Next 2Y19.42%
EPS Next 3Y16.11%
EPS Next 5Y11.81%
Revenue Next Year-17.06%
Revenue Next 2Y2.18%
Revenue Next 3Y10.25%
Revenue Next 5Y16.75%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for PACB. In the last year negative earnings were reported.
Also next year PACB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PACB's earnings are expected to grow with 16.11% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.42%
EPS Next 3Y16.11%
5. Dividend
5.1 Amount
No dividends for PACB!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PACIFIC BIOSCIENCES OF CALIF
NASDAQ:PACB (11/22/2024, 8:00:02 PM)
After market: 1.84 +0.04 (+2.22%)1.8
+0.03 (+1.69%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap492.95M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -27.19% | ||
| ROE | -87.01% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 23.81% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.12
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.97 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 9.74 | ||
| Quick Ratio | 8.64 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-11.02%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-7.52%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)2.15%
Revenue growth 3Y36.47%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y